Dr. Brian G.M. Durie discusses key takeaways from the annual conference and explains how this new and important information relates to myeloma patients, caregivers, and other members of the myeloma community.

This teleconference is sponsored by an educational grant from:
​Amgen, Celgene Corporation,  Janssen, and Takeda Oncology


Previous Post
ASH 2016: A negative study is great news for patients
Next Post
IMWG: Who should be treated?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.